PAI-1 and HER2 interaction in advanced breast cancer disease: evidence for added benefit from trastuzumab in HER2-negative patients.

about

Diabetes-associated dysregulated cytokines and cancer.

P2860

Q55331908-75632A51-7821-4CF2-BCB0-461F5B998F68

P2860

PAI-1 and HER2 interaction in advanced breast cancer disease: evidence for added benefit from trastuzumab in HER2-negative patients.

Item

http://www.wikidata.org/entity/Q38462629

description

2015 nî lūn-bûn

@nan

2015年の論文

@ja

2015年論文

@yue

2015年論文

@zh-hant

2015年論文

@zh-hk

2015年論文

@zh-mo

2015年論文

@zh-tw

2015年论文

@wuu

2015年论文

@zh

2015年论文

@zh-cn

name

PAI-1 and HER2 interaction in ...... mab in HER2-negative patients.

@en

type

Item

label

PAI-1 and HER2 interaction in ...... mab in HER2-negative patients.

@en

prefLabel

PAI-1 and HER2 interaction in ...... mab in HER2-negative patients.

@en

P1476

PAI-1 and HER2 interaction in ...... umab in HER2-negative patients

@en

P2093

Anna Batistatou

http://www.w3.org/2001/XMLSchema#string

Dimitrios Bafaloukos

http://www.w3.org/2001/XMLSchema#string

Dimitrios Pectasides

http://www.w3.org/2001/XMLSchema#string

Eleni Galani

http://www.w3.org/2001/XMLSchema#string

Evangelia Razis

http://www.w3.org/2001/XMLSchema#string

George Fountzilas

http://www.w3.org/2001/XMLSchema#string

George Pentheroudakis

http://www.w3.org/2001/XMLSchema#string

Georgia Gourgioti

http://www.w3.org/2001/XMLSchema#string

Georgia Karayannopoulou

http://www.w3.org/2001/XMLSchema#string

Gerasimos Aravantinos

http://www.w3.org/2001/XMLSchema#string

P2860

American Society of Clinical Oncology/College Of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer

American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer.

Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update.

Tissue microarray technology for high-throughput molecular profiling of cancer.

HER2 and chromosome 17 effect on patient outcome in the N9831 adjuvant trastuzumab trial.

uPAR and HER-2 gene status in individual breast cancer cells from blood and tissues.

External quality assessment of trans-European multicentre antigen determinations (enzyme-linked immunosorbent assay) of urokinase-type plasminogen activator (uPA) and its type 1 inhibitor (PAI-1) in human breast cancer tissue extracts

Protumorigenic activity of plasminogen activator inhibitor-1 through an antiapoptotic function

Immunohistochemistry and fluorescence in situ hybridization assessment of HER2 in clinical trials of adjuvant therapy for breast cancer (NCCTG N9831, BCIRG 006, and BCIRG 005).

American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer.

P2888

s00280-015-2762-3

P304

1289-1301

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S00280-015-2762-3

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

P577

2015-05-07T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P6179

1034779850

http://www.w3.org/2001/XMLSchema#string

P698

25947084

http://www.w3.org/2001/XMLSchema#string

PAI-1 and HER2 interaction in advanced breast cancer disease: evidence for added benefit from trastuzumab in HER2-negative patients.

about

P2860

P2860

PAI-1 and HER2 interaction in advanced breast cancer disease: evidence for added benefit from trastuzumab in HER2-negative patients.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P433

P478

P50

P577

P6179

P698

P356

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P433

P478

P50

P577

P6179

P698